Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Menée auprès de 54 897 hommes ou femmes en bonne santé invités, entre 1993 et 2011, à participer pour la première fois à un examen de dépistage du cancer de la prostate, du poumon, du côlon-rectum ou de l'ovaire (âge : 55 à 74 ans), cette étude américaine évalue le taux de non participation puis identifie les facteurs prédictifs associés
Objective : Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Method : PLCO was conducted from 1993-2011 at 10 US institutions. A total of 154,897 healthy men and women ages 55-74 years were randomized. Intervention arm participants were invited to receive gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from screening center).
Results : The rate of non-compliance was 11% overall but varied by screening center. Significant associations were observed for most covariates but indicated modest increases or decreases in odds. An exception was use of a two-step consent process (consented intervention arm participants for exams after randomization) relative to a one-step process (consented all participants prior to randomization) (OR: 2.2, 95% CI: 2.0-2.5). Non-compliance percentages increased with further distance from screening centers, but ORs were not significantly different from 1.
Conclusions : Many factors modestly influenced compliance. Consent process was the strongest predictor of compliance.
Preventive Medicine , résumé, 2013